Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers

Abstract

While advances in the treatment of pediatric cancers have improved survival to > 80% across all tumor types, drug resistance continues to limit survival for a considerable number of patients. We review the known mechanisms of resistance in pediatric cancers, including processes that impair conventional chemotherapies, newer classes of targeted small molecule antineoplastic drugs, and monoclonal antibodies. We highlight similarities and differences in treatment approach and resistance between pediatric and adult cancers. We also discuss newer areas of research into drug resistance, including extracellular and immune factors.

Keywords

Tumor microenvironment / drug efflux / chemoresistance / inhibition of apoptosis / BCL2 / pediatric cancer

References

[1] Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda MD, based on November 2018 SEER data submission, posted to the SEER web site, April 2019. Avaliable from: https://seer.cancer.gov/csr/1975_2016/ [Last accessed on 26 June 2019]

[2] Adamson PC.Improving the outcome for children with cancer: development of targeted new agents..CA Cancer J Clin2015;65:212-20 PMCID:PMC4629487

[3] Vaupel PW.The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia..Klin Padiatr1997;209:243-9

[4] Emadi A,Brodsky RA.Cyclophosphamide and cancer: golden anniversary..Nat Rev Clin Oncol2009;6:638-47

[5] Stewart CF,Crom R,Heideman RL.Topoisomerase I interactive drugs in children with cancer..Invest New Drugs1996;14:37-47

[6] Masetti R,Zama D,Martoni A.Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma..Adv Ther2012;29:747-62

[7] Isakoff MS,Meltzer P.Osteosarcoma: current treatment and a collaborative pathway to success..J Clin Oncol2015;33:3029-35 PMCID:PMC4979196

[8] Jakacki RI,Buxton A,Burger PC.Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study..Neuro Oncol2016;18:1442-50 PMCID:PMC5035517

[9] Lipshultz SE,Franco VI.Treatment-related cardiotoxicity in survivors of childhood cancer..Nat Rev Clin Oncol2013;10:697-710

[10] Okabe M,Harigae H,Okitsu Y.Characterization of the organic cation transporter SLC22A16: a doxorubicin importer..Biochem Biophys Res Commun2005;333:754-62

[11] Zhao H,Deng M,Li Y.Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption..Oncotarget2016;7:85515-28 PMCID:PMC5356754

[12] Hayes FA,Mauer AM.Correlation of cell kinetic and clinical response to chemotherapy in disseminated neuroblastoma..Cancer Res1977;37:3766-70

[13] Gröbner SN,Weischenfeldt J,Kleinheinz K.The landscape of genomic alterations across childhood cancers..Nature2018;555:321-7

[14] Fruhwald MC.The epigenetics of cancer in children..Klin Padiatr2008;220:333-41

[15] Moore SW.Developmental genes and cancer in children..Pediatr Blood Cancer2009;52:755-60

[16] Lawlor ER.Epigenetic changes in pediatric solid tumors: promising new targets..Clin Cancer Res2012;18:2768-79 PMCID:PMC3691809

[17] Yiu TT.Pediatric cancer epigenome and the influence of folate..Epigenomics2015;7:961-73 PMCID:PMC4636966

[18] La Madrid AM.Epigenetics in clinical management of children and adolescents with brain tumors..Curr Cancer Drug Targets2018;18:57-64

[19] Nordlund J.Epigenetics in pediatric acute lymphoblastic leukemia..Semin Cancer Biol2018;51:129-38

[20] Filbin M.Developmental origins and emerging therapeutic opportunities for childhood cancer..Nat Med2019;25:367-76

[21] Schleiermacher G,London WB,Brodeur GM.Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project..Br J Cancer2012;107:1418-22 PMCID:PMC3494425

[22] Chicard M,Colmet Daage L,Gentien D.Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma..Clin Cancer Res2016;22:5564-73

[23] Defferrari R,Ambros IM,Bedwell C.Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification..Br J Cancer2015;112:290-5 PMCID:PMC4453444

[24] Squire JA,Marrano P,Bayani J.High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays..Genes Chromosomes Cancer2003;38:215-25

[25] Smida J,Zhang Y,Ribi S.Genome-wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma..Int J Cancer2017;141:816-28

[26] Behjati S,Haase K,Young MD.Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma..Nat Commun2017;8:15936 PMCID:PMC5490007

[27] Ratnaparkhe M,Wei PC,Kolb T.Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors..Nat Commun2018;9:4760 PMCID:PMC6232171

[28] Rausch T,Zapatka M,Zichner T.Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations..Cell2012;148:59-71 PMCID:PMC3332216

[29] Gratias EJ,Jennings LJ,Tian J.Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: a report from the children’s oncology group..J Clin Oncol2016;34:3189-94 PMCID:PMC5012705

[30] Radtke I,Ishii M,Cheng J.Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia..Proc Natl Acad Sci U S A2009;106:12944-9 PMCID:PMC2716382

[31] Farber S.Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer..Blood1949;4:160-7

[32] Price CH,Salzer-Kuntschik M,Willert HG.Osteosarcoma in children. A study of 125 cases..J Bone Joint Surg Br1975;57:341-5

[33] Smith M,Trimble EL.Dose Intensity of Chemotherapy for Childhood Cancers..Oncologist1996;1:293-304

[34] Neil EC,Khakoo Y.Neurological Complications of Pediatric Cancer..J Child Neurol2016;31:1412-20 PMCID:PMC4927408

[35] Weyl-Ben-Arush M.The price of the successful treatment of pediatric malignancies..Curr Pediatr Rev2017;13:4-7

[36] Pluimakers VG,Neggers S.Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors..Crit Rev Oncol Hematol2019;133:129-41

[37] Roeca C,Polotsky AJ.Recommendations for assessing ovarian health and fertility potential in survivors of childhood cancer..Maturitas2019;122:57-9

[38] Sklar CA,Chemaitilly W,Follin C.Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an endocrine society clinical practice guideline..J Clin Endocrinol Metab2018;103:2761-84

[39] Dixon SB,Alberts NM,Brinkman TM.Factors influencing risk-based care of the childhood cancer survivor in the 21st century..CA Cancer J Clin2018;68:133-52

[40] Ehrhardt MJ,Bjornard KL.Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma..Br J Haematol2019;185:1099-110

[41] Ekhart C,Rodenhuis S,Beijnen JH.Influence of p olymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide..Pharmacogenet Genomics2008;18:515-23

[42] Algeciras-Schimnich A,Snozek CL.Pharmacogenomics of tamoxifen and irinotecan therapies..Clin Lab Med2008;28:553-67

[43] Queckenberg C,Baken BC,Wargenau M.Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations..Cancer Chemother Pharmacol2015;76:1081-91

[44] de Man FM,van Schaik RHN,Bins S.Individualization of Irinotecan Treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics..Clin Pharmacokinet2018;57:1229-54 PMCID:PMC6132501

[45] Mittal B,Kumar S,Agarwal G.Cytochrome P450 in Cancer Susceptibility and Treatment..Adv Clin Chem2015;71:77-139

[46] Sim SC,Ingelman-Sundberg M.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects..Pharmacogenomics J2013;13:1-11

[47] Alini TP,Antonio SP,Reynaldo JGF.CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response..Oncotarget2017;8:38530-40 PMCID:PMC5503551

[48] Melanie MH,Hans G,Hanneke IV.A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment..Clin Cancer Res2015;21:3436-41

[49] Valencia-Cervantes J,Aquino-Jarquín G,Martínez-Fong D.Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxiainducible factor 1alphamediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation..Oncol Rep2019;41:178-90 PMCID:PMC6278548

[50] Darwish MH,Farhat GN,Ghandour FA.Association of CYP3A4/5 genotypes and expression with the survival of patients with neuroblastoma..Mol Med Rep2015;11:1462-68

[51] Egbelakin A,MacGill EA,Topletz AR.Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia..Pediatr Blood Cancer2011;56:361-7 PMCID:PMC3020258

[52] Araoz HV,Foncuberta ME,Alonso CN.Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina..Leuk Lymphoma2015;56:1370-78

[53] Borst L,Dalhoff K,Wesenberg F.The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia..Eur J Haematol2011;86:477-83

[54] Gezsi A,Erdelyi DJ,Antal P.In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia..Pharmacogenomics J2015;15:241-47

[55] Sims RP.The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia..J Oncol Pharm Pract2016;22:76-81

[56] Lennard L,Van Loon J.Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia..Lancet1990;336:225-9

[57] Lennard L.Implementation of TPMT testing..Br J Clin Pharmacol2014;77:704-14 PMCID:PMC3971986

[58] Mlakar V,Satyanarayana Uppugunduri CR,Ansari M.Pharmacogenomics in pediatric oncology: review of gene-drug associations for clinical use..Int J Mol Sci2016;17:E1502 PMCID:PMC5037779

[59] Roninson IB,Choi KG,Housman DE.Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells..Proc Natl Acad Sci U S A1986;83:4538-42 PMCID:PMC323769

[60] Goldstein LJ,Ueda K,Green A.Expression of the multidrug resistance, MDR1, gene in neuroblastomas..J Clin Oncol1990;8:128-36

[61] Nooter K,Oostrum R,Hagenbeek T.Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A..Int J Cancer1990;45:263-8

[62] Benard J,de Vathaire F,Terrier-Lacombe MJ.Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis..Prog Clin Biol Res1994;385:111-6

[63] Gsur A,Gotzl M,Lechner K.MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update..Leuk Lymphoma1993;12:91-4

[64] Wunder JS,Wold L.Expression of the multidrug resistance gene in osteosarcoma: a pilot study..J Orthop Res1993;11:396-403

[65] Pirker R,Geissler K,Haas OA.MDR1 gene expression and treatment outcome in acute myeloid leukemia..J Natl Cancer Inst1991;83:708-12

[66] Molina-Ortiz D,Cardenas-Cardos R,Hernandez-Arrazola D.MDR1 not CYP3A4 gene expression is the predominant mechanism of innate drug resistance in pediatric soft tissue sarcoma patients..Cancer Biomark2018;22:317-24

[67] Chan HS,Thorner PS,Lin YP.P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma..N Engl J Med1991;325:1608-14

[68] Hodorova I,Vecanova J,Plank L.Relation between expression pattern of wild-type p53 and multidrug resistance proteins in human nephroblastomas..Acta Histochem2013;115:273-8

[69] Fazlina N,Zarina AL,Zulkifli SZ.Assessment of P-gp and MRP1 activities using MultiDrugQuant Assay Kit: a preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients..Malays J Pathol2008;30:87-93

[70] Kourti M,Gombakis N,Tzimagiorgis G.Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia..Int J Hematol2007;86:166-73

[71] Haber M,Bordow SB,Cohn SL.Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma..J Clin Oncol2006;24:1546-53

[72] Li Y,Li N,Zhou H.miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1..Oncol Rep2017;37:2193-200

[73] Hontecillas-Prieto L,Vaca DP,Marcilla D.Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients..Oncotarget2017;8:11173-86 PMCID:PMC5355255

[74] Ruiz-Pinto S,Patino-Garcia A,Alonso J.Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome..Ann Oncol2016;27:1788-93

[75] Kuss BJ,Cole SP,Kopecky KJ.The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias..Leuk Lymphoma1996;20:357-64

[76] Oda Y,Radig K,Mittler U.Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours..Virchows Arch1997;430:99-105

[77] El-Sharnouby JA,El Ghannam DM,Hagag AA.Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia..J Oncol Pharm Pract2010;16:179-88

[78] Steinbach D,Voigt A,Zintl F.BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia..Leukemia2002;16:1443-47

[79] Rodrigo MAM,Jimenez AMJ,Babula P.Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells..Cells2019;8:E235 PMCID:PMC6469049

[80] Ferrandis E,Riou G.Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse..Cancer Res1994;54:2256-61

[81] Haber M,Haber PS,Stewart BW.The prognostic value of MDR1 gene expression in primary untreated neuroblastoma..Eur J Cancer1997;33:2031-36

[82] Xi G,Grahovac G,Wadhwani N.Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy..Mol Cancer2017;16: PMCID:PMC5282778

[83] Dabaghi M,Moshtaghian J,Abedi M.Overexpression of SORCIN is a Prognostic Biomarker for Multidrug-Resistant Pediatric Acute Lymphoblastic Leukemia and Correlates with Upregulated MDR1/P-gp..Genet Test Mol Biomarkers2016;20:516-21

[84] Hu R,Li Q,Jin W.Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells..Int J Hematol2010;92:105-10

[85] Shi CJ,Ren MF,Yan YY.Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation..Leuk Res2011;35:73-9

[86] Warmann S,Teichmann B,Gratz KF.The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model..Cancer2002;95:1795-801

[87] Janiszewska H,Kolodziej B,Haus O.Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia..Ann Hematol2009;88:1193-98

[88] Pongstaporn W,Chaksangchaichote P,Hongeng.MDR1 C3435T and C1236T polymorphisms: association with high-risk childhood acute lymphoblastic leukemia..Asian Pac J Cancer Prev2015;16:2839-43

[89] Schaich M,Pfirrmann M,Illmer T.A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients..Ann Oncol2009;20:175-81

[90] Jamroziak K,Balcerczak E,Trelinska J.Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia..Eur J Haematol2004;72:314-21

[91] Chung ES,Sohn S,Baik HH.GT1b-induced neurotoxicity is mediated by the Akt/GSK-3/tau signaling pathway but not caspase-3 in mesencephalic dopaminergic neurons..BMC Neurosci2010;11:74 PMCID:PMC2894844

[92] Mhaidat NM,Khabour OF,Matalka II.Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin’s Lymphoma..J Exp Clin Cancer Res2011;30:68 PMCID:PMC3154152

[93] Jamroziak K.Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia?.Leuk Res2008;32:1173-75

[94] Yue Q,Chen L,Bu F.MDR1 C3435T polymorphism and childhood acute lymphoblastic leukemia susceptibility: an updated meta-analysis..Biomed Pharmacother2015;69:76-81

[95] Howell SB,Larson CA.Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs..Mol Pharmacol2010;77:887-94 PMCID:PMC3202487

[96] Giacomini KM,Tweedie DJ.Membrane transporters in drug development..Nat Rev Drug Discov2010;9:215-36 PMCID:PMC3326076

[97] Fox E,Pastakia D,Yang SX.Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors..Cancer Chemother Pharmacol2015;76:1273-83

[98] Harper JW.The DNA damage response: ten years after..Mol Cell2007;28:739-45

[99] Chen X,Pappo A,Dalton J.Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma..Cell Rep2014;7:104-12 PMCID:PMC4096827

[100] Wasserman JD,Eichler-Jonsson C,Rodriguez-Galindo C.Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children’s oncology group study..J Clin Oncol2015;33:602-9 PMCID:PMC4517369

[101] Malkin D.Li-fraumeni syndrome..Genes Cancer2011;2:475-84 PMCID:PMC3135649

[102] Izycka-Swieszewska E,Stefanowicz J,Szutowicz-Zielinska E.Malignant Gliomas as Second Neoplasms in Pediatric Cancer Survivors: Neuropathological Study..Biomed Res Int2018;2018:4596812 PMCID:PMC5899852

[103] Pollack IF,Woods J,Holmes EJ.Expression of p53 and prognosis in children with malignant gliomas..N Engl J Med2002;346:420-7

[104] Ackermann S,Hero B,Kahlert Y.A mechanistic classification of clinical phenotypes in neuroblastoma..Science2018;362:1165-70

[105] Cattelani S,Galavotti S,Tanno B.The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform..Neoplasia2012;14:634-43 PMCID:PMC3421959

[106] Layfield LJ,Dodge RK.Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFr--a survival study..J Surg Oncol1995;59:21-27

[107] Veschi V,Voss TC,Gryder B.Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma..Cancer Cell2017;31:50-63 PMCID:PMC5233415

[108] Felix CA,Provisor D,Sexsmith EA.The p53 gene in pediatric therapy-related leukemia and myelodysplasia..Blood1996;87:4376-81

[109] Yoshizato T,Atsuta Y,Iijima-Yamashita Y.Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation..Blood2017;129:2347-58 PMCID:PMC5409449

[110] Takagi M,Nemoto Y,Tsuchida R.Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor..J Natl Cancer Inst2017;109:

[111] Ballinger ML,Ray-Coquard I,Mitchell G.Monogenic and polygenic determinants of sarcoma risk: an international genetic study..Lancet Oncol2016;17:1261-71

[112] Chen C,Gombert M,Binder V.Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients..Leuk Res2015;39:990-1001

[113] Richmond J,Evans K,Mendomo A.Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia..Clin Cancer Res2015;21:1395-405 PMCID:PMC4359964

[114] Gu L,Findley HW.MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2..Leukemia2008;22:730-9 PMCID:PMC3477706

[115] Zhou M,Findley HW,Woods WG.PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells..Cancer Res2003;63:6357-62

[116] Inomistova MV,Khranovska NM,Gorbach OI.Prognostic significance of MDM2 gene expression in childhood neuroblastoma..Exp Oncol2015;37:111-5

[117] McEvoy JD.Genetic and Epigenetic Discoveries in Human Retinoblastoma..Crit Rev Oncog2015;20:217-25 PMCID:PMC5458782

[118] Kang MH,Kolb EA,Carol H.Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program..Pediatr Blood Cancer2016;63:1744-52 PMCID:PMC5657425

[119] Tisato V,Gonelli A,Zauli G.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer..J Hematol Oncol2017;10:133 PMCID:PMC5496368

[120] Zhou M,Abshire TC,Billett AL.Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia..Leukemia2000;14:61-7

[121] Gamble LD,Tweddle DA.MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63..Oncogene2012;31:752-63 PMCID:PMC3191119

[122] Cole KA,Laquaglia M,Russell MR.RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma..Proc Natl Acad Sci U S A2011;108:3336-41 PMCID:PMC3044382

[123] Hoglund A,Muralidharan SV,Merta P.Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells..Clin Cancer Res2011;17:7067-79

[124] Hattinger CM,Sella F,Benini S.Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy..Histopathology2015;67:338-47

[125] Lowery CD,Dowless M,Falcon BL.The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma..Clin Cancer Res2017;23:4354-63

[126] Zhang Q,Li BJ,Wei F.Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma..Genet Mol Res2015;14:11235-41

[127] Chen Z,Yao D,Cao WM.Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis..Sci Rep2016;6:38011 PMCID:PMC5171816

[128] Sarmento LM,Nascimento R,Antunes I.CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress..Oncogene2015;34:2978-90

[129] Duan Y,Nie J,Lu F.Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway..Oncol Lett2018;16:5473-81 PMCID:PMC6144465

[130] Matheson CJ,Amani V,Backos DS.A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells..ACS Chem Biol2016;11:921-30

[131] Mueller S,Yang X,Olow AK.Targeting Wee1 for the treatment of pediatric high-grade gliomas..Neuro Oncol2014;16:352-60 PMCID:PMC3922515

[132] Sanmartin E,Piqueras M,Berlanga P.Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition..Clin Cancer Res2017;23:6875-87

[133] https://clinicaltrials.gov/ct2/results?term=PARP&Search=Apply&age_v=&age=0&gndr=&type=&rslt=

[134] https://clinicaltrials.gov/ct2/results?cond=&term=wee1&cntry=&state=&city=&dist=&Search=Search&age=0

[135] Tsai WC,Lin CR,Gao HW.Nrf2 Expressions Correlate with WHO Grades in Gliomas and Meningiomas..Int J Mol Sci2016;17:E722 PMCID:PMC4881544

[136] Park JY,Park YK.Nrf2 expression is associated with poor outcome in osteosarcoma..Pathology2012;44:617-21

[137] Zhang J,Wu W,Wang B.Expression of the Nrf2 and Keap1 proteins and their clinical significance in osteosarcoma..Biochem Biophys Res Commun2016;473:42-6

[138] Bortolozzi R,Rampazzo E,Maule F.AKR1C enzymes sustain therapy resistance in paediatric T-ALL..Br J Cancer2018;118:985-94 PMCID:PMC5931104

[139] Klein S,Bulvik B,Weiss ID.CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways..Cancer Res2018;78:1471-83

[140] Laetsch TW,Vu A,Vido M.Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma..Cell Death Dis2014;5:e1072 PMCID:PMC3944256

[141] Aries IM,Karim SA,Hinze L.PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia..J Exp Med2018;215:3094-114 PMCID:PMC6279404

[142] Ham J,Sano R,Sennott EM.Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination..Cancer Cell2016;29:159-72 PMCID:PMC4749542

[143] Jubierre L,Planells-Ferrer L,Tenbaum SP.BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways..Oncogene2016;35:5179-90

[144] Lestini BJ,Fluchel MN,Chen NL.Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists..Cancer Biol Ther2009;8:1587-95 PMCID:PMC3770183

[145] Avgeris M,Kontos CK,Marmarinos A.BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia..Clin Chem Lab Med2018;56:2104-18

[146] Jing D,Beck D,Yakob NA.Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells..Blood2015;125:273-83

[147] Tahir IM,Jamil A.Association of BCL-2 with oxidative stress and total antioxidant status in pediatric acute lymphoblastic leukemia..J Biol Regul Homeost Agents2017;31:1023-27

[148] Pedersen MO,Brown P,Knudsen H.Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers..PLoS One2017;12:e0186983 PMCID:PMC5663399

[149] Prutsch N,Suske T,Schlederer M.Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma..Leukemia2019;33:696-709

[150] Karpel-Massler G,Bianchetti E,Shu C.Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL..Nat Commun2017;8:1067 PMCID:PMC5651864

[151] Das P,Suri V,Sharma BS.Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-Myc, ERBB2, and anti-apoptotic proteins along with histological typing and clinical outcome..Childs Nerv Syst2009;25:825-35

[152] McLendon RE,Fuchs HE,Bigner SH.Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study..Histopathology1999;34:154-62

[153] Thallinger C,Maierhofer H,Pehamberger H.Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide..Clin Cancer Res2004;10:4185-91

[154] Krskova L,Brizova H,Sumerauer D.Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma..Cancer Genet Cytogenet2009;193:1-8

[155] Haydn T,Schuele R.Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells..Cell Death Dis2017;8:e2879 PMCID:PMC5520898

[156] Javaheri T,Pencik J,Kauer M.Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation..Cell Death Dis2016;7:e2419 PMCID:PMC5133963

[157] Sanchez R,Lalonde ME,Richer C.Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia..Haematologica2014;99:314-21 PMCID:PMC3912962

[158] Marston E,Jesson J,McConville C.Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response..Blood2009;113:117-26

[159] Holleman A,Kazemier KM,von Bergh AR.Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia..Blood2005;106:1817-23

[160] Grotzer MA,Zuzak TJ,Marwaha S.Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression..Oncogene2000;19:4604-10

[161] Teitz T,Kidd VJ.Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death..J Mol Med (Berl)2001;79:428-36

[162] Dukers DF,ten Berge RL,Ossenkoppele GJ.High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome..Blood2002;100:36-42

[163] Pingoud-Meier C,Janss AJ,Phillips PC.Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma..Clin Cancer Res2003;9:6401-09

[164] Konopleva M,Potluri J,Hogdal L.Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia..Cancer Discov2016;6:1106-17 PMCID:PMC5436271

[165] Jain N,Thompson P,Burger J.Ibrutinib and Venetoclax for First-Line Treatment of CLL..N Engl J Med2019;380:2095-103

[166] Coutre S,Furman RR,Heffner L.Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy..Blood2018;131:1704-11 PMCID:PMC5922273

[167] Place AE,Bourquin JP,Gore L.Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies..Future Oncol2018;14:2115-29

[168] Huether R,Chen X,Parker M.The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes..Nat Commun2014;5:3630 PMCID:PMC4119022

[169] McKenna ES.Epigenetics and cancer without genomic instability..Cell Cycle2009;8:23-6

[170] Thirman MJ,Burnett RC,McCabe NR.Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations..N Engl J Med1993;329:909-14

[171] Peterson JF,Pearce KE,Benevides Demasi JC.KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory..Genes Chromosomes Cancer2018;57:541-6

[172] Bernt KM,Sinha AU,Faber J.MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L..Cancer Cell2011;20:66-78 PMCID:PMC3329803

[173] Li Z,Setyawati AN,Haruta M.EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications..Oncogene2018;37:2714-27 PMCID:PMC5955864

[174] Chen L,Dharia NV,Iniguez AB.CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2..J Clin Invest2018;128:446-62 PMCID:PMC5749506

[175] Wang C,Woo CW,Wang L.EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR..Cancer Res2012;72:315-24 PMCID:PMC3487161

[176] Feng Z,Zhou C,Wu F.Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia..J Hematol Oncol2016;9:24 PMCID:PMC4789278

[177] Bennani-Baiti IM,Llombart-Bosch A.Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma..Hum Pathol2012;43:1300-7

[178] Sankar S,Bearss J,Hoffman LM.Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth..Clin Cancer Res2014;20:4584-97 PMCID:PMC4155010

[179] Gao C,Liu SG,Cui L.Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia..Eur J Haematol2017;99:150-9

[180] Robinson G,Kranenburg TA,Chen X.Novel mutations target distinct subgroups of medulloblastoma..Nature2012;488:43-8 PMCID:PMC3412905

[181] Viaene AN,Rosenbaum J,Surrey LF.SETD2 mutations in primary central nervous system tumors..Acta Neuropathol Commun2018;6:123 PMCID:PMC6231273

[182] Zhu X,Zeng H,Chen A.Identification of functional cooperative mutations of SETD2 in human acute leukemia..Nat Genet2014;46:287-93 PMCID:PMC4440318

[183] Olar A,Mehta VP,Manekia JH.ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features..Clin Neuropathol2019;38:59-73

[184] Cheung NK,Lu C,Bahrami A.Association of age at diagnosis and genetic mutations in patients with neuroblastoma..JAMA2012;307:1062-71 PMCID:PMC3527076

[185] Pages M,Boddaert N,Besnard A.Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma..Brain Pathol2018;28:103-11

[186] Gielen GH,Hammes J,Waha A.H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas..Am J Clin Pathol2013;139:345-9

[187] Schwartzentruber J,Liu XY,Pfaff E.Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma..Nature2012;482:226-31

[188] Lucio-Eterovic AK,Valera ET,Queiroz RG.Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas..BMC Cancer2008;8:243 PMCID:PMC2536671

[189] Oehme I,Wegener D,Linke JP.Histone deacetylase 8 in neuroblastoma tumorigenesis..Clin Cancer Res2009;15:91-9

[190] Wittenburg LA,Thamm D.A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma..J Cell Biochem2012;113:773-83 PMCID:PMC4667946

[191] Warrell RP, Jr,Richon V,Pandolfi P.Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase..J Natl Cancer Inst1998;90:1621-5

[192] Bhatla T,Morrison DJ,Burke MJ.Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia..Blood2012;119:5201-10 PMCID:PMC3369610

[193] Shukla N,O’Brien MM,Brown P.Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia..Blood2016;128:2780

[194] Fouladi M,Stewart CF,Schaiquevich P.Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report..J Clin Oncol2010;28:3623-9 PMCID:PMC2917318

[195] Witt O,Deubzer HE,Witt R.Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia..Klin Padiatr2012;224:398-403

[196] Muscal JA,Horton TM,Ahern CH.A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children’s Oncology Group phase I consortium study (ADVL0916)..Pediatr Blood Cancer2013;60:390-5 PMCID:PMC3511610

[197] Hummel TR,Ahern C,Reid JM.A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children’s Oncology Group phase 1 consortium study..Pediatr Blood Cancer2013;60:1452-7 PMCID:PMC4139006

[198] DuBois SG,Park JR,Yang X.Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma..Clin Cancer Res2015;21:2715-21 PMCID:PMC4470833

[199] https://clinicaltrials.gov/ct2/results?term=ezh2&age_v=&age=0&gndr=&type=&rslt=&Search=Apply

[200] https://clinicaltrials.gov/ct2/show/NCT03600649?term=lsd1&age=0&rank=2

[201] Gabra MM.microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview..Front Oncol2017;7:255 PMCID:PMC5674931

[202] Galardi A,Businaro P,Locatelli F.MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential..Curr Med Chem2018;25:584-600

[203] Kumar V,McGuire T,Sharp JG.Challenges and Recent Advances in Medulloblastoma Therapy..Trends Pharmacol Sci2017;38:1061-84

[204] Tarek N,Salvador L,Herzog CE.Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen..Pediatr Blood Cancer2018;65:1

[205] Becher OJ,Khakoo Y,Haque S.A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors..Pediatr Blood Cancer2017;64:7

[206] Vo KT,Nasholm NM,Hollinger F.Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors..Oncotarget2017;8:23851-61 PMCID:PMC5410349

[207] Krueger DA,Holland K,Tudor C.Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis..N Engl J Med2010;363:1801-11

[208] Bagatell R,Ingle AM,Voss S.Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children’s Oncology Group Study..Pediatr Blood Cancer2014;61:833-9 PMCID:PMC4196713

[209] Rodrik-Outmezguine VS,Yao Z,McWhirter C.Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor..Nature2016;534:272-6 PMCID:PMC4902179

[210] Hosoi H,Liu LN,Shikata T.Studies on the mechanism of resistance to rapamycin in human cancer cells..Mol Pharmacol1998;54:815-24

[211] Folgiero V,Carai A,Alfano V.IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma..Oncotarget2016;7:52900-11 PMCID:PMC5288157

[212] Pelloski CE,Zhang L,Colman H.Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma..Clin Cancer Res2006;12:3935-41

[213] Alvarenga AW,Rodrigues BR,Sanemastu P.Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades..J Histochem Cytochem2017;65:93-103 PMCID:PMC5256195

[214] King D,Bryant H.PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma..J Pediatr Hematol Oncol2015;37:245-51

[215] Miyahara H,Natsumeda M,Rodgers L.The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma..Cancer Lett2017;400:110-6 PMCID:PMC5569904

[216] Flannery PC,Amani V,Lemma RT.Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma..Oncol Rep2018;39:455-64 PMCID:PMC5783612

[217] Akgul S,Zheng S,Treisman DM.Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma..Cell Rep2018;24:463-78 PMCID:PMC6116735

[218] Talpaz M,Druker BJ,Gambacorti-Passerini C.Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study..Blood2002;99:1928-37

[219] Schultz KR,Heerema NA,Aledo A.Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031..Leukemia2014;28:1467-71 PMCID:PMC4282929

[220] Rutkowski P,Chou AJ.Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series..BMC Cancer2017;17:717 PMCID:PMC5674814

[221] Wedekind MF,Shah N.Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma..Pediatr Blood Cancer2017;64:11

[222] Truffaux N,Paulsson J,Guerrini-Rousseau L.Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma..Neuro Oncol2015;17:953-64 PMCID:PMC5654348

[223] Glade Bender JL,Reid JM,Roberts T.Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group phase I consortium report..J Clin Oncol2013;31:3034-43 PMCID:PMC3739862

[224] Yang K.Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review..Crit Rev Oncol Hematol2015;93:277-92

[225] Aoe M,Muraoka M,Nakamura Y.ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases..Int J Hematol2014;99:609-15

[226] Zwaan CM,Mechinaud F,Lehrnbecher T.Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium..J Clin Oncol2013;31:2460-8

[227] Bresler SC,Huwe PJ,Krytska K.ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma..Cancer Cell2014;26:682-94 PMCID:PMC4269829

[228] Tucker ER,Innocenti P.Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic..Cancer Res2015;75:2770-4 PMCID:PMC4539575

[229] Sabnis AJ.Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology..Trends Mol Med2019;25:185-97 PMCID:PMC6401263

[230] Cooper J.Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance..Cancer Cell2019;35:347-67

[231] Marona P,Kotlinowski J,Jura J.C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas..Cells2019;8:E272 PMCID:PMC6468372

[232] Harivenkatesh N,Bakhshi S,Kabra M.Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia..Pharmacol Res2017;120:138-45

[233] Brown LM,Khaw SL.Dysregulation of BCL-2 family proteins by leukemia fusion genes..J Biol Chem2017;292:14325-33 PMCID:PMC5582828

[234] Morgillo F,Fasano M.Mechanisms of resistance to EGFR-targeted drugs: lung cancer..ESMO Open2016;1:e000060 PMCID:PMC5070275

[235] Yu AL,Ozkaynak MF,Kreissman SG.Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma..N Engl J Med2010;363:1324-34 PMCID:PMC3086629

[236] Shusterman S,Gillies SD,Voss SD.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study..J Clin Oncol2010;28:4969-75 PMCID:PMC3020698

[237] Cheung NK,Kushner BH,Chamberlain E.Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission..J Clin Oncol2012;30:3264-70 PMCID:PMC3434986

[238] Mody R,Van Ryn C,London WB.Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial..Lancet Oncol17;18:946-57 PMCID:PMC5527694

[239] Goldman S,Galardy P,Frazer JK.Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report..Br J Haematol2014;167:394-401 PMCID:PMC4198418

[240] Meinhardt A,Zimmermann M,Kontny U.Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia..J Clin Oncol2010;28:3115-21

[241] Locatelli F,Neville K,Beishuizen A.Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study..Lancet Haematol18;5:450-61

[242] Anderson PM,Gorlick RG,Daw NC.A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma..Pediatr Blood Cancer2016;63:1761-70 PMCID:PMC5129487

[243] Pappo AS,Crowley JJ,Hogendoorn PC.A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study..Cancer2014;120:2448-56

[244] Peters KB,Miller E,McSherry F.Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas..J Neurooncol2018;137:349-56

[245] Navid F,Neel M,Shulkin BL.A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy..Int J Cancer2017;141:1469-77 PMCID:PMC5812455

[246] DeWire M,Turner DC,Hawkins C.An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)..J Neurooncol2015;123:85-91 PMCID:PMC4992988

[247] Hiraga J,Sugimoto T,Ito M.Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance..Blood2009;113:4885-93

[248] Al-Rohil RN,Patel A,Ivan D.Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding..J Cutan Pathol2016;43:1161-6

[249] Grupp SA,Barrett D,Porter DL.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia..N Engl J Med2013;368:1509-18 PMCID:PMC4058440

[250] Ozkaynak MF,Krailo MD,Javorsky B.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children’s Cancer Group Study..J Clin Oncol2000;18:4077-85

[251] Desai AV,Smith LM,Maris JM.Pharmacokinetics of the chimeric anti-GD2 antibody, ch14..Cancer Chemother Pharmacol2014;74:1047-55

[252] Cheung IY,Modak S,Roberts SS.Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival..Oncoimmunology2017;6:1358331 PMCID:PMC5674972

[253] van der Sluis IM,Te Loo M,van den Bos C.coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group..Pediatr Blood Cancer2018;65:27083

[254] Paillassa J,Thomas X,Audrain M.Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial..Blood Cancer J2018;8:45 PMCID:PMC5966449

[255] Tram Henriksen L,Schmiegelow K,Skov Wehner P.Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation..Pediatr Blood Cancer2017;64:12

[256] Schleiermacher G,Bernard V,Cappo J.Emergence of new ALK mutations at relapse of neuroblastoma..J Clin Oncol2014;32:2727-34

[257] Bellini A,Leroy Q,Pierron G.Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis..Clin Cancer Res2015;21:4913-21

[258] Chen L,Turnbull L,Schleiermacher G.Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse..Oncotarget2016;7:87301-11 PMCID:PMC5349989

[259] Mehrazma M,Kalantari E,Hendi A.Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray..Fetal Pediatr Pathol2013;32:192-204

[260] Choi SA,Phi JH,Park CK.A distinct subpopulation within CD133 positive brain tumor cells shares characteristics with endothelial progenitor cells..Cancer Lett2012;324:221-30

[261] Toren A,Jacob-Hirsch J,Kreiser D.CD133-positive hematopoietic stem cell “stemness” genes contain many genes mutated or abnormally expressed in leukemia..Stem Cells2005;23:1142-53

[262] Sartelet H,Nyalendo C,Annabi B.CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway..Histopathology2012;60:1144-55

[263] Bahnassy AA,El-Wakil M,Abdel-Sayed A.Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data..Transl Res2015;165:396-406

[264] Friedman GK,Nan L,Etminan T.Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses..Neuro Oncol2016;18:227-35 PMCID:PMC5472147

[265] Zambo I,Zapletalova D,Mudry P.Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas..Cancer Biomark2016;17:107-16

[266] O’Hagan-Wong K,Carrier-Leclerc A,Hamdy R.Increased IL-6 secretion by aged human mesenchymal stromal cells disrupts hematopoietic stem and progenitor cells’ homeostasis..Oncotarget2016;7:13285-96 PMCID:PMC4924641

[267] Zhang LJ,Gao YM,Wu R.The expression of IL-6 and STAT3 might predict progression and unfavorable prognosis in Wilms’ tumor..Biochem Biophys Res Commun2013;435:408-13

[268] Bid HK,Cam M,Kurmasheva RT.DeltaNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis..Cancer Res2014;74:320-9 PMCID:PMC3950294

[269] Gross AC,Phelps DA,Bid HK.IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis..JCI Insight2018;3:99791 PMCID:PMC6141177

[270] Samuel P,Carter D.Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles..Proteomics2017;17:23-4

[271] Mittapalli RK,Parrish KE,Halvorson KG.ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model..Mol Cancer Ther2016;15:819-29 PMCID:PMC4873451

[272] Ingram WJ,Little EB,Harliwong I.ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma..Exp Hematol Oncol2013;2:26 PMCID:PMC3851566

[273] Asgharzadeh S,Ji L,Fischer M.Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma..J Clin Oncol2012;30:3525-32 PMCID:PMC3675667

[274] Majzner RG,Grosso JF,Pawel BR.Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues..Cancer2017;123:3807-15

[275] Fujiwara T,Yamamoto S,Setsu N.Macrophage infiltration predicts a poor prognosis for human ewing sarcoma..Am J Pathol2011;179:1157-70 PMCID:PMC3157220

[276] Alanee S,Vijai J,Hamilton R.Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer..Fam Cancer2013;12:597-600 PMCID:PMC5073797

[277] Li X,Huang X,Shi Q.Helios expression in regulatory T cells promotes immunosuppression, angiogenesis and the growth of leukemia cells in pediatric acute lymphoblastic leukemia..Leuk Res2018;67:60-6

[278] Rigo V,Daga A,Corrias MV.Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma..Sci Rep2017;7:14049 PMCID:PMC5656588

[279] Parsons E,Ong’echa JM,Vulule J.Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study..PLoS One2016;11:e0167841 PMCID:PMC5199096

[280] Mao Y,Blanc KL,Kogner P.Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma..Clin Cancer Res2016;22:3849-59

[281] Salem ML,Abdou SH,Sobhy SM.Chemotherapy alters the increased numbers of myeloid-derived suppressor and regulatory T cells in children with acute lymphoblastic leukemia..Immunopharmacol Immunotoxicol2018;40:158-67

[282] Long AH,Cui Y,Walker AJ.Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas..Cancer Immunol Res2016;4:869-80 PMCID:PMC5050151

[283] Houghton PJ,Tucker C,Favours E.The pediatric preclinical testing program: description of models and early testing results..Pediatr Blood Cancer2007;49:928-40